Drug Profile
Research programme: erythroferrone modulators - Silarus Therapeutics
Alternative Names: Iron metabolism disorders therapeutics - Silarus TherapeuticsLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer Silarus Therapeutics
- Class
- Mechanism of Action Hormone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Iron deficiency anaemia; Iron overload
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Iron deficiency anaemia in USA
- 28 Oct 2018 No recent reports of development identified for research development in Iron-overload in USA
- 22 Sep 2014 Early research in Iron overload in USA (unspecified route)